Science and Research

Mesenchymal stem cells attenuate inflammatory processes in the heart and lung via inhibition of TNF signaling

Mesenchymal stem cells (MSC) have been used to treat different clinical conditions although the mechanisms by which pathogenetic processes are affected are still poorly understood. We have previously analyzed the homing of bone marrow-derived MSC to diseased tissues characterized by a high degree of mononuclear cell infiltration and postulated that MSC might modulate inflammatory responses. Here, we demonstrate that MSC mitigate adverse tissue remodeling, improve organ function, and extend lifespan in a mouse model of inflammatory dilative cardiomyopathy (DCM). Furthermore, MSC attenuate Lipopolysaccharide-induced acute lung injury indicating a general role in the suppression of inflammatory processes. We found that MSC released sTNF-RI, which suppressed activation of the NFkappaBp65 pathway in cardiomyocytes during DCM in vivo. Substitution of MSC by recombinant soluble TNF-R partially recapitulated the beneficial effects of MSC while knockdown of TNF-R prevented MSC-mediated suppression of the NFkappaBp65 pathway and improvement of tissue pathology. We conclude that sTNF-RI is a major part of the paracrine machinery by which MSC effect local inflammatory reactions.

  • Martire, A.; Bedada, F. B.; Uchida, S.; Poling, J.; Kruger, M.; Warnecke, H.; Richter, M.; Kubin, T.; Herold, S.; Braun, T.

Keywords

  • Acute lung injury
  • Fibrosis
  • Heart failure
  • Inflammation
  • Mesenchymal stem cells
  • Proteomics
  • TNF-alpha
Publication details
DOI: 10.1007/s00395-016-0573-2
Journal: Basic research in cardiology
Pages: 54 
Number: 5
Work Type: Original
Location: UGMLC
Disease Area: PALI
Partner / Member: JLU, MPI-BN
Access-Number: 27435289
See publication on PubMed

DZL Engagements

chevron-down